Abstract
It has been previously found that local administration of Balb/c plasmacytoma cells transformed and made non-tumorigenic by insertion of the cloned murine interleukin-2 (IL-2) gene induced regressions of a variety of murine tumours including the original Balb/c plasmacytoma X63-Ag8.653 growing in syngeneic mice. The tumour-inhibitory effect of the plasmacytoma cells transformed by IL-2 cDNA and designated as X63-m-IL-2 was due to their high constitutive production of IL-2. Here we show that admixture of syngeneic spleen cells to the X63-m-IL-2 transformants substantially (P<0.025) increased the antitumour efficacy of the transformants. Balb/c spleen cells co-cultivated with X63-m-IL-2 cells in vitro yielded predominantly Thy 1.2+, CD3+, LFA-1+ lymphocytes, cytolytic for the X63-Ag8.653 plasmacytoma as well as for other murine tumours, including the X63-m-IL-2 target cells.
Key words: Interleukin-2, Plasmacytoma, Immunotherapy
Abbreviations
- IL-2
interleukin-2
- LAK
lymphokine-activated killer
- NK
natural killer
- HPRT
hypoxanthine phosphoribosyl transferase
- HAT
hypoxanthine/aminopterin/thymidine
References
- Blankenstein T, Qin Z, Überla K, Müller T, Rosen H, Volk H-D, Diamantstein T (1991) Tumor suppression after tumor cell-target tumor necrosis factor alpha gene transfer. J Exp Med 173:1047–1052 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bubeník J (1990) Local and regional immunotherapy of cancer with interleukin 2 (guest editorial). J Cancer Res Clin Oncol 116:1–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bubeník J, Indrová M (1987) The anti-tumour efficacy of human recombinant interleukin-2: correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin-2 immunotherapy in vivo. Cancer Immunol Immunother 24:269–271 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bubeník J, Šímová J, Jandlová T (1989/1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23:287–292 [DOI] [PubMed] [Google Scholar]
- Bubeník J, Lotzová E, Zeuthen J, Bubeníková D, Šímová J, Indrová M (1991) Gene therapy of cancer: use of interleukin-2 (IL-2) gene transfer in local immunotherapy. J Exp Clin Cancer Res 10:213–220 [Google Scholar]
- Bubeník J, Zeuthen J, Šímová J, Jandlová T, Bubeníková D, Radzikowski C (1992) Activation and phenotyping of LAK generated by exposure to product of cells transformed by interleukin 2 cDNA. Anticancer Res 12:965–968 [PubMed] [Google Scholar]
- Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403 [DOI] [PubMed] [Google Scholar]
- Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217–1224 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goldie H, Butler Ch, Anderson MM (1953) Growth characteristics of free C1498 (granulocytic leukemia) tumor cells in the peritoneal fluid and the blood of C57 mice. Cancer Res 13:125–129 [PubMed] [Google Scholar]
- Karasuyama H, Melchers F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2,3,4 or 5, using modified cDNA expression vectors. Eur J Immunol 18:97–104 [DOI] [PubMed] [Google Scholar]
- Kearney JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550 [PubMed] [Google Scholar]
- Kedar E, Herberman RB (1982) Induction of NK-like anti-tumor reactivity in vitro and in vivo by IL-2. In: Herberman RB (ed) NK cells and other natural effector cells. Academic Press. New York, pp 859–861 [Google Scholar]
- Mulé JJ, Yang J, Shu S, Rosenberg SA (1986) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136:3899–3903 [PubMed] [Google Scholar]
- Rosenberg S, Lotze MT (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4:681–713 [DOI] [PubMed] [Google Scholar]
- Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512 [DOI] [PubMed] [Google Scholar]
- Wigzell H, Ramstedt U (1986) Natural killer cells. In: Weyr MM (ed) Cellular immunology, vol 2. Blackwell Scientific, Oxford, pp 601–609 [Google Scholar]